Skip to content

Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)

Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI) for Patients Having a Low Versus High Proportion of Hyaluronan Binding Sperm (HBA)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00741494
Enrollment
801
Registered
2008-08-26
Start date
2008-08-31
Completion date
Unknown
Last updated
2010-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Factor Infertility

Keywords

infertility, ICSI, hyaluronan binding, sperm, sperm selection, male factor, hyaluronan, sperm maturity, clinical pregnancy rates, hyaluronan binding assay, HBA, PICSI

Brief summary

The purpose of this study is to determine if using microdots of hyaluronan (PICSI) to select sperm for ICSI will result in increased pregnancies especially with men that have a low hyaluronan binding score (HBA).

Interventions

Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI

Sponsors

Biocoat
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* IVF patients who require the ICSI procedure and whose care is being managed by the clinical and scientific staff of the participating groups, will be included in the study.

Exclusion criteria

* IVF patients who do not require the ICSI procedure will be excluded from the study. In addition the following groups of patients will also be excluded: * Patients using testicular sperm. * Patients using donor sperm. * Patients where the female partner is over 40 years of age * Patients who have an initial HBA score less than or equal to 2% * Patients who have a sperm count less than or equal to 10,000 motile sperm per ml. * Patients who produce less than 4 Metaphase II oocytes

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate8 weeks post ICSI

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026